PTLA News and Press, Portola Pharmaceuticals Inc. From 03/20/19

SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire from the Board of Directors. Dr. Homcy co-founded the Company in 2003...

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39 th Annual Heal...

Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call March 01, 2019 08:30 AM ET Company Participants Cara Miller - Vice President of Investor Relations and Corporate Communications Scott Garland - President and Chief Executive Officer Mardi Dier - Chief Financial O...

Puma Biotechnology (NYSE: PBYI ) +30%  on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...

Portola Pharmaceuticals ( PTLA ) Q4 results : Revenues: $15.3M (+56.1%); Product revenue: $14.1M; Collaboration and license revenue: $1.2M. More news on: Portola Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q4 Non-GAAP EPS of -$1.04 beats by $0.07 ; GAAP EPS of -$1.34 misses by $0.23 . More news on: Portola Pharmaceuticals, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

– Fourth Quarter Andexxa ® Revenues of $14.0 Million;  Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May – – Sign...

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that it has entered into a $125 million loan agreement with HealthCare Royalty Partners (HCR) and investment funds manager Athyrium Capital Management, LP. ...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Portola Pharmaceuticals' (NASDAQ: PTLA ) Factor Xa reversal agent Ondexxya (andexanet alfa). More news on: Portola Pharmaceuticals, Healthcare stocks news, Stocks on the move, ...

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authoriz...